An academic second-generation CAR T-cell construct targeting BCMA reported an 86% overall response rate in patients with relapsed or refractory systemic light chain amyloidosis, according to research published in the Journal of Hematology and Oncology. The study evaluated the in-house manufactured high-avidity product MDC-CAR-BCMA001, with six of seven treated patients achieving responses and three achieving complete remissions with negative measurable residual disease. All participants experienced cytokine release syndrome, mostly grade 2 or lower, with resolution after tocilizumab, dexamethasone, or both. Investigators reported multi-organ hematologic improvements—spanning cardiac, renal, and neurologic manifestations—corresponding with rapid suppression of amyloidogenic free light chains. With Europe lacking approved BCMA-directed CAR T products for this specific indication, the data add to the evidence base for cellular approaches in AL amyloidosis, although small sample size and the need for longer follow-up remain central limitations.